Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on specific share transactions rather than general financial performance.
Material Changes
There are no material changes to financial performance reported. The filing details an increase in Ordinary share ADR interests for specific individuals following the re-investment of dividends paid on October 8, 2009.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly reports compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: October 20, 2009.
- Transaction Type: Increase in Ordinary share ADR interests via dividend re-investment.
- Price per ADR: $39.58.
- Individuals Notified: Mr. E J Gray (14.58 ADRs) and Mr. D J Phelan (442.09 ADRs).
- Dividend Date: October 8, 2009.